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A B S T R A C T
Giardia lamblia is a protozoan parasite that causes giardiasis, a diarrhoeal disease affecting humans and
various animal species. Nitro drugs such as the nitroimidazole metronidazole and the nitrothiazolide
nitazoxanide are used for treatment of giardiasis. Nitroreductases such as GlNR1 and GlNR2 may play a
role in activation or inactivation of these drugs. The aim of this work is to characterise these two enyzmes
using functional assays. For respective analyses recombinant analogues from GlNR1 and GlNR2 were pro-
duced in Escherichia coli. E. coli expressing GlNR1 and GlNR2 alone or together were grown in the presence
of nitro compounds. Furthermore, pull-down assays were performed using HA-tagged GlNR1 and GlNR2
as baits. As expected, E. coli expressing GlNR1 were more susceptible to metronidazole under aerobic and
semi-aerobic and to nitazoxanide under semi-aerobic growth conditions whereas E. coli expressing GlNR2
were susceptible to neither drug. Interestingly, expression of both nitroreductases gave the same results
as expression of GlNR2 alone. In functional assays, both nitroreductases had their strongest activities on
the quinone menadione (vitamin K3) and FAD, but reduction of nitro compounds including the nitro drugs
metronidazole and nitazoxanidewas clearly detected. Full reduction of 7-nitrocoumarin to 7-aminocoumarin
was preferentially achieved with GlNR2. Pull-down assays revealed that GlNR1 and GlNR2 interacted in
vivo forming a multienzyme complex. These ﬁndings suggest that both nitroreductases are multifunc-
tional. Their main biological role may reside in the reduction of vitamin K analogues and FAD. Activation
by GlNR1 or inactivation by GlNR2 of nitro drugs may be the consequence of a secondary enzymatic ac-
tivity either yielding (GlNR1) or eliminating (GlNR2) toxic intermediates after reduction of these compounds.
© 2015 Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Giardia lamblia (syn.Giardia duodenalis;Giardia intestinalis), a ﬂag-
ellated protozoan, is themost common causative agent of persistent
diarrhoeaworldwide (Thompson, 2000; Robertson et al., 2010). Cur-
rently, anti-giardial chemotherapy is performed using a couple of
effective drugs, namely, the nitroheterocyclic drugs tinidazole, met-
ronidazole, furazolidone,quinacrine, theaminoglycosideparomomycin,
and the benzimidazole albendazole (Wright et al., 2003; Lalle, 2010).
Furthermore, the nitrothiazolide nitazoxanide has been introduced
as an alternative option (Hemphill et al., 2006).
As frequently hypothesised, metronidazole and other nitro drugs
are reduced to a nitro-radical. According to one of these hypotheses,
electrons are provided by the enzyme pyruvate:ﬂavodoxin/ferredoxin
oxidoreductase (PFOR), representing a protein that is lacking in higher
eukaryotic cells (Brown et al., 1998; Horner et al., 1999). Referring
to this model, the electrons are transferred via PFOR from pyruvate
to ferredoxin. The resulting reduced ferredoxin is then re-oxidised
by ferredoxin:NAD-oxidoreductase transferring its electrons to
NAD(P). The resulting NAD(P)H serves as a redox partner for
subsequent reactions such as the reduction of O2 by NAD(P)H oxidase
(Brown et al., 1998). Nitro drugs may interfere in this pathway and
capture electrons directly from the reduced ferredoxin or from the
NAD(P)H-oxidase. This process leads to the accumulation of toxic
radicals that cause irreversible damage in the parasite. Further
evidence for PFOR being a major target for nitro drugs in Giardia
comes from metronidazole-resistant isolates with lower PFOR
expression levels (Upcroft and Upcroft, 2001).
Since a few years, however, evidence is emerging that PFORmay
not represent the exclusive target of nitro drugs in semi-aerobic or
anaerobic pathogens. In the case of T. vaginalis, metronidazole and
other nitroimidazoles were shown to covalently bind, and thus in-
activate, proteins involved in the thioredoxin reductase pathway.
Resistant cells compensate this blocking by re-regulating PFORs and
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other enzymes participating in oxidoreductive processes. Accord-
ingly, down-regulation of PFOR seems not to be a prerequisite but
rather a consequence of resistance formation (Leitsch et al., 2009).
Moreover, our investigations on Giardia cell lines resistant to nitro
drugs have demonstrated that resistance is not necessarily linked
to down-regulation of PFOR (Müller et al., 2007a, 2008). Although
some nitro drugs are supposed to interact with PFOR in a direct
manner, direct reduction of the nitro group via ferredoxin is rather
unlikely. Accordingly, catalysis of this reaction by nitroreductases
is a more realistic scenario (Roldán et al., 2008).
Nitroreductases belong to the enzymatic repertoire of many ar-
chaebacteria and eubacteria (Nixon et al., 2002), where they
contribute to the assimilation of nitro compounds as carbon sources
(Johnson and Spain, 2003; Luque-Almagro et al., 2006). From amech-
anistic point of view, nitroreductases are divided into two classes,
namely oxygen-sensitive and oxygen-insensitive nitroreductases
(Roldán et al., 2008). Oxygen-sensitive nitroreductases transfer elec-
trons one by one from NAD(P)H to the nitro group. In presence of
oxygen, the intermediate radicals are re-oxydised. Thus, there is
NAD(P)H consumptionwithout nitroreduction, and the reaction looks
most like the one catalysed by a NAD(P)H oxydase. Oxygen-
insensitive nitroreductases catalyse the full reduction of nitro
compounds into the corresponding amines by two-electron trans-
fers. Also this type of reaction produces toxic intermediates, namely,
nitroso or hydroxylamine intermediates (Moreno and Docampo,
1985).
In anaerobic or microaerophilic pathogens, nitroreductases are
also well documented as resistance factors. In Helicobacter pylori,
resistance to metronidazole is associated with loss-of-function mu-
tations of the gene rdxA encoding an oxygen-insensitive
nitroreductase (Goodwin et al., 1998), which reduces metronida-
zole under anaerobic conditions (Olekhnovich et al., 2009). Other
nitroreductases are found in enteric bacteria including Escherichia
coli (Lee et al., 1994; Zenno et al., 1996a, 1996b, 1996c; Guillén et al.,
2009; Tavares et al., 2009; Yanto et al., 2010).
Nitroreductases have also been identiﬁed in microaerophilic or
anaerobic eukaryotic parasites such as Entamoeba histolytica and
G. lamblia. These organisms may have acquired the respective genes
from prokaryotes by lateral transfer (Nixon et al., 2002). G. lamblia
(cloneWB C6) harbours two genes encoding nitroreductases GlNR1
(accession N° EDO80257; Gl50803-22677, referred to as Fd-NR2 in
the Giardia database) and GlNR2 (accession N° XM_764091.1;
Gl50803-6175, referred to as Fd-NR1 in the Giardia database). The
polypeptide sequence of GlNR2 is rather similar to that one of GlNR1.
Both proteins contain a ferredoxin domain with four Fe-S-clusters
at their N-terminus and a nitro-FMN-reductase domain at their
C-terminus. Our previous results suggest that both enzymes have
a different action on nitro drugs: GlNR1 behaving as an activator
(Müller et al., 2007b; Nillius et al., 2011), GlNR2 more as an
inactivator (Müller et al., 2013). The biological role of these enzymes
is, however, completely unclear.
Here, we present results from functional assays showing that both
nitroreductases are multifunctional with strong quinone reduc-
tase activities. Moreover, we show that both nitroreductases interact
in vivo forming a multienzyme complex.
2. Materials and methods
2.1. Tissue culture media, biochemicals and drugs
If not otherwise stated, all biochemical reagents were from Sigma
(St Louis, MO, USA). 7-Nitrocoumarin was purchased from Santa
Cruz Biotechnology (Dallas, Texas, USA). Nitazoxanide was
synthesised at the Department of Chemistry and Biochemistry,
University of Berne (kindly provided by Ch. Leumann). The
nitroimidazole C17 was kindly provided by J. A. Upcroft (Molecular
Genetics Laboratory, Queensland Institute of Medical Research,
Brisbane, Australia). CB1954 was purchased from Santa Cruz
Biotechnology. The compounds were kept as 100mM stock solutions
in DMSO at −20 °C.
2.2. Overexpression of recombinant GlNR1 and 2 in E. coli and
His-Tag-puriﬁcation
Overexpression of recombinant GlNR1 and GlNR2 in E. coli BL21
(DE3) and their puriﬁcation by His-Tag-aﬃnity-chromatography was
performed as previously described (Müller et al., 2007b, 2013).
2.3. Overexpression of recombinant HA-tagged GlNR1 and 2 in
G. lamblia
Cloning of PCR-ampliﬁed GlNR1 and GlNR2 open reading frames
into the XbaI and PacI sites from vector pPacV-Integ (Jiménez-García
et al., 2008) was essentially done as previously described (Müller
et al., 2007b, 2009). Brieﬂy, GlNR1 and GlNR2-speciﬁc forward primer
contained the XbaI site followed by the constitutive glutamate de-
hydrogenase (GDH) promoter sequence (Davis-Hayman and Nash,
2002) (Table S1). In the reverse primer, a sequence encoding three
consecutive human inﬂuenza haemagglutinin (HA) tags was intro-
duced 5′ of the PacI site (Table S1). PCRs for ampliﬁcation of GlNR1
and GlNR2 open reading frames, insertion of ampliﬁcation prod-
ucts into XbaI and PacI sites from pPacV thus yielding pPacV-GlNR1-
3xHA or pPacV-GlNR2-3xHA, and transfection of G. lamblia WBC6
with Swa1-linearised recombinant plasmids were performed as pre-
viously described (Müller et al., 2007b, 2009).
2.4. Co-immunoprecipitation assay with HA-tagged nitroreductases
G. lamblia WBC6 GlNR1-3xHA and GlNR2-3xHA transgenic
trophozoites were grown under anaerobic condition in triple ﬂasks
(Nunc, cat. 132867). The parasites were harvested by chilling in ice
water for an hour followed by centrifugation (900 × g, 10 min, 4 °C),
washed in 50 ml ice cold PBS, and counted in a Neubauer chamber.
For co-immunoprecipitation assays, 109 parasites were then re-
suspended in a 15-ml-Falcon-tube containing 5 ml of lysis buffer
(RIPA) consisting of 50 mM Tris pH 7.4, 150 mM NaCl, 1% IGEPAL,
0.5% sodium deoxycholate, 0.1% SDS, 10 mM EDTA supplemented
with 2 mM phenylmethylsulfonyl ﬂuoride, PMSF and 1X Protease
Inhibitor cocktail, PIC (cat. No. 539131, Calbiochem USA), and
sonicated twice (60 pulses, 2 output control, 30% duty cycle and 60
pulses, 4 output control, 40% duty cycle). To solubilise the proteins,
the Falcon tube was incubated on a rotating wheel (1 h, 4 °C). Cell
lysate was transferred into 1.5 ml microtubes and the supernatant
containing the solubilised protein was collected after high-speed
centrifugation (14,000 × g, 10 min, 4 °C). The solubilised protein
fraction was diluted 1:1 with detergent-free RIPA lysis buffer
supplemented with 2% Triton-X-100. To this diluted protein lysate,
40 μl anti-HA agarose bead slurry from the Pierce HA Tag IP/Co-IP
Kit (Thermo Fisher Scientiﬁc, Rockford, Il.) were added and incubated
at 4 °C for 2 h on a rotating wheel in order to allow the HA-tagged
proteins to bind to the agarose beads. Samples were pulse-
centrifuged at 3500 g at 4 °C and 100 μl was stored as ﬂow though
control. Samples were washed 4 times with 3 ml of Tris-Buffered
Saline (TBS) supplemented with 0.1% Triton-X-100 and once with
3 ml PBS. The agarose slurry was re-suspended in 350 μl PBS and
transferred into the spin column provided in the kit and pulse-fuged
at 14,000 × g for 10 s at 4 °C. The agarose beads (boiled beads) were
then re-suspended in 30 μl PBS and transferred into a 1.5 ml
microtubes and stored at −20 °C overnight for further analysis.
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2.5. Protein analysis and sample preparation for mass spectrometry
For SDS-PAGE according to (Laemmli (1970), the samples collected
as described above were suspended in one volume of SDS-PAGE
sample buffer containing 100mMdithiothreitol, and boiled for 5min
followed by high speed centrifugation (14,000 × g, 10 min, RT). For
MS analysis, 25 μl of boiled bead sample were loaded on a 12%
polyacrylamide gel under reducing conditions. The gel (see Fig. S1)
was then stained with Instant blue (Expedeon, San Diego, CA),
de-stainedwith sterile water, and subsequently sent to the Functional
Genomics Center Zürich for mass spectrometry. For immunoblot
analysis, approximately 107 trophozoites were processed and samples
were collected as described above. Immunoblots were performed
with rabbit anti-GlNR1 (Nillius et al., 2011) and mouse-anti-HA
(Roche Diagnostics, Rotkreuz, Switzerland) antibodies as described
before (Nillius et al., 2011).
2.6. Mass spectrometry
Gel lanes (see Fig. S1) were cut in 8 equal sections. Each section
was further diced into smaller pieces and washed twice with 100 μl
of 100mMammoniumbicarbonate/50%acetonitrile for15minat50 °C.
The sections were dehydrated with 50 μl of acetonitrile. The super-
natants of the washing and de-hydration steps were discarded.
The gel pieceswere re-hydratedwith 20 μl trypsin solution (5 ng/ μl
in 10 mM Tris/2 mM CaCl2 at pH 8.2) and 40 μl buffer (10 mM
Tris/2 mM CaCl2 at pH 8.2). Microwave-assisted digestion was per-
formed for 30minat 60 °Cwith themicrowavepower set to5W(CEM
Discover, CEMCorp., USA). Supernatantswere collected in fresh tubes
and the gel pieces were extracted with 150 μl of 0.1% triﬂuoroacetic
acid/50% acetonitrile. Supernatants were combined, dried, and the
samplesweredissolved in20 μl of 0.1% formic acidbeforebeing trans-
ferred to the autosampler vials for liquid chromatography-tandem
mass spectrometry, 7 to 9 μl were injected. Samples weremeasured
onaQ-exactivemass spectrometer (ThermoFisherScientiﬁc)equipped
with a nanoAcquity UPLC (Waters Corporation, Milford, MA). Pep-
tides were trapped on a trap column (Symmetry C18, 5 μm,
180 μm × 20mm, Waters Corporation) before they were separated
on a BEH300 C18, 1.7 μm, 75 μm × 150mm column (Waters Corpo-
ration) by applying a gradient formedbetween solvent A (0.1% formic
acid inwater) and solvent B (0.1% formic acid in acetonitrile). On the
mass spectrometer, a gradient starting at 1% solvent B and increas-
ing to 40% within 60min was established. Database searches were
performedusing theMASCOT search programagainst theGiardia da-
tabase (http://giardiadb.org/giardiadb/) with a concatenated decoy
database supplementedwith commonly observed contaminants and
the Swissprot database to increase size of the database. The identi-
ﬁedhitswere then loadedonto theScaffoldViewerversion4 (Proteome
Software, Portland,USA) and thehitswereﬁlteredbasedonhigh strin-
gency parameters, namely, minimal mascot score of 95 for peptide
probability, a protein probability of 95% and aminimum of 2 unique
peptides per protein.
2.7. Quantiﬁcation of nitroreductase activity
For enzymatic quantiﬁcation, the nitroreductase activity wasmea-
sured in 96-well microtiter plates containing 100 μl of a reaction
mix containing buffer (50 mM Tris-Cl−, pH 7.0), 0.1 mM of the com-
pounds to be tested, 0.5 mM thiazolyl blue tetrazolium (MTT),
0.5 mM NADH or NADPH and 0.1 to 0.2 μg of the recombinant
enzymes. The plates were incubated at 37 °C under aerobic condi-
tions or in an anaerobic growth chamber. Substrate and enzyme
blanks were included. After different time points, the reaction was
stopped by adding 100 μl of pure ethanol thus solubilising the
product formed by the reduction of MTT, formazan. The absor-
bance at 590 nm was read on a 96-well plate spectrophotometer
(Versamax; Molecular Devices, Sunnyvale, CA). After subtraction of
substrate and enzyme blanks, nitroreductase activity was ex-
pressed as ΔA590/min/mg (Prochaska and Santamaria, 1988).
The reduction of 7-nitrocoumarin to 7-aminocoumarin was quan-
tiﬁed using the reaction mix as described above, but without MTT,
with the same volumes and under the same conditions of incuba-
tion. Enzyme and substrate blanks were included. The reaction was
stopped by adding 100 μl of 50 mM HCl. The resulting solution had
pH 2 resulting in full protonation of 7-aminocoumarin which was
quantiﬁed by ﬂuorimetry with excitation at 365 nm and emission
at 455 nm (Wagner, 2009) using a 96-well-multimode plate reader
(Enspire; Perkin-Elmer, Waltham, MA).
2.8. Determination of drug susceptibility in E. coli
Drug susceptibility of recombinant E. coli BL21 (DE3) lines
(Invitrogen, Carlsbad, CA, USA) expressing either GlNR1 (recombinant
plasmid pGlNR1), GlNR2 (pGlNR2), glucuronidase A (pGusA) alone
(Nillius et al., 2011; Müller et al., 2013) or both nitroreductases (this
study, see below)were tested as described (Müller et al., 2013). Single
gene expression was achieved in vector system pET151 Directional
TOPO® (Invitrogen) containing the ampicillin resistance marker for
selection of transformants and allowing IPTG-inducible over-
expression of recombinant proteins (see pET151 Directional TOPO®
manual provided by the manufacturer) as described (Müller et al.,
2013). In order to achieve double transfectants expressing both
nitroreductases, the following cloning strategies were chosen: (i) the
entire pET151 Directional TOPO® expression cassettes carrying GlNR1
and GusA open reading frames were ampliﬁed by PCR using
T7 forward (5′-TAATACGACTCACTATAGGG-3′) and T7 reverse
(5′-TAGTTATTGCTCAGCGGTGG-3′) primers (annealing to regions
ﬂanking the expression cassette of pET151 Directional TOPO®) and
pGlNR1 and pGusA as DNA templates. (ii) PCR products were used
for re-cloning of GlNR1 and GusA into pCR-Blunt II-TOPO®
(Invitrogen) containing a kanamycin resistance marker. (iii) This
re-cloning step provided plasmid constructs, pGlNR1-KanR and
pGusA-KanR, suitable for subsequent transformation of ampicillin-
resistant BL21 (DE3)/pGlNR2, and BL21 (DE3)/pGusA strains by
selection for ampicillin (100 μg/ml)/kanamycin (50 μg/ml) double-
resistant clones. E. coli BL21 (DE3) carrying pGlNR1, pGlNR2, pGusA,
pNR1-KanR/pGlNR2 and pGusA-KanR/pGusA were tested under
aerobic or microaerobic (5% O2, 10% CO2, 85% N2) conditions by a
conventional disc diffusion agar procedure as described (Müller et al.,
2013). Growth inhibition zone diameters were determined and the
inhibition zone around the disc was calculated (in mm2).
2.9. Statistical methods
Statistical analysis of the results was done based on the tools from
the open source software package R (R Core Team, 2012) Differ-
ences exhibiting p values < 0.01 were considered signiﬁcant.
3. Results
3.1. E. coli expressing recombinant GlNR1 and GlNR2 have different
susceptibilities to nitro drugs
We generated recombinant E. coli lines producing GlNR1 or GlNR2
alone (Müller et al., 2013) or both (this study). As a control, we have
created recombinant lines expressing glucuronidase A (Gus) alone
(Müller et al., 2013) or double (Gus/Gus) (this study). In a pilot ex-
periment, overproduction of proteins induced by IPTG strongly
reduced growth of E. coli. Accordingly, non-induced, recombinant
E. coli cultures were chosen for growth inhibition assays as de-
scribed earlier (Nillius et al., 2011). With these ﬁve strains, disc
diffusion assays were performed with metronidazole, nitazoxanide
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or tetracyclin as a positive control under aerobic or semi-aerobic
conditions. Under aerobic as well as semi-aerobic growth condi-
tions, metronidazole clearly inhibited growth of control strains
transformed with Gus or Gus/Gus. In the presence of GlNR1 alone,
this susceptibility was signiﬁcantly enhanced. Bacteria trans-
formed with GlNR2 alone or with both nitroreductases were
completely resistant to metronidazole. Under aerobic conditions,
nitazoxanide did not affect growth of bacteria. Under semi-aerobic
conditions, however, bacteria expressing GlNR1 exhibited a signiﬁ-
cantly higher susceptibility to nitazoxanide than control bacteria.
Other inserts than GlNR1 had no effects. There were no signiﬁcant
effects in nitroreductase-transformed strains vs. control strains in
the presence of tetracycline (Fig. 1).
3.2. Recombinant GlNR1 and GlNR2 are quinone reductases
The results obtained with metronidazole clearly suggested a role
of both nitroreductases under aerobic conditions. Was their role
thus restricted to the reduction of nitro compounds? To answer
this question we implemented a functional assay based on the re-
duction of MTT to formazan by reduced nitrocompounds or quinones.
In a ﬁrst experiment, we incubated the assays in a 37 °C incubator
under normal atmosphere or in an anaerobic culture chamber
(100% N2). We offered NADH as electron donor, the quinone
menadion and dinitrotoluene as electron acceptors or DMSO as a
solvent control. Interestingly, both nitroreductases reduced mena-
dione, and this even to much higher extents than dinitrotoluene.
Both enzymes worked evenly well under anaerobic and under
aerobic conditions (Fig. 2).
3.3. Both nitroreductases are NADH dependent and have a
preference for menadione
We tested the preference for NADH or NADPH as electron donors
withmenadione or dinitrotoluene as a substrate. Both nitroreductases
had clearly a preference for NADHwith both substrates (Table 1). In
a next step, we determined the activities of both enzymes on a series
of compounds including FAD, dicoumarol, quinacrine and various nitro
compounds including the antigiardial drugs metronidazole and
nitazoxanide as well as C17 and CB1954. Furthermore, we included
7-nitrocoumarin, a compound yielding the highly ﬂuorescent
7-aminocoumarin upon complete reduction.
The highest activities were observed for both enzymes with
menadione as a substrate. Dicoumarol, a typical inhibitor of mam-
malian quinone reductases (Müller and Hemphill, 2011), had no
effects. The second best substrate in our series was FAD. Ubiqui-
none (coenzyme Q10) was also reduced by both enzymes but with
lower speciﬁc activities than meandione (Table 1).
With respect to nitro compounds as substrates, 7-nitrocoumarin
was clearly the best. Interestingly, we could detect a reduction of
all nitrocompounds with antigiardial activity, i.e. metronidazole,
nitazoxanide, and C17. Dinitrophenol was only reduced by GlNR1.
GlNR1 had a higher speciﬁc activity with all substrates (Table 1).
Fig. 1. Susceptibility of E. coli BL21 (DE3) expressing GusA as a control (Gus), GlNR1
(NR1), and GlNR2 (NR2), two GusA (Gus/Gus), or both nitroreductases (NR1/NR2) to
metronidazole (MET) and to nitazoxanide (NTZ). Tetracycline (TET) was included as
a positive control. Plates with different cell lines exposed to discs containing the drugs
were incubated under aerobic (A) or semi-aerobic (B) conditions. After 24 h, diam-
eters of inhibition zones were determined. Mean values ± SE are given for 3 replicates.
Values marked by asterisks are signiﬁcantly different from the controls, i.e. to Gus for
the single transformants and to Gus/Gus for the double transformant (paired t-test,
two-sided, *p < 0.01).
Fig. 2. Activity of recombinant G. lamblia nitroreductases GlNR1 (NR1) and GlNR2
(NR2) with menadione (Men) or dinitrotoluene (DNT) as substrates (0.1 mM). DMSO
was included as a solvent control, thus as a substrate blank. Functional assays were
performed with NADH as an electron donor and MTT as chromogenic electron
acceptor. The reaction was performed at 37 °C under normal atmosphere (aerobic)
or in an anaerobic chamber (100% N2; anaerobic) and stopped after 2 h addition of
one volume pure ethanol. Mean values (±SE) are given for three replicates.
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3.4. 7-nitrocoumarin is fully reduced preferentially by GlNR2
Theseresultspromptedus to investigatewhether7-aminocoumarin
was fully reduced by both nitroreductases thus yielding the ﬂuores-
cent7-aminocoumarin. For thispurpose,weperformedthesameassay
as above without MTT, and quantiﬁed the ﬂuorescent product. Al-
though GlNR2 had a lower speciﬁc activity in the assay as des-
cribed above, it was twice as active as GlNR1 in fully reducing
7-aminocoumarin. When added together, both enzymes were more
active than the sum of the single activities (Fig. 3).
3.5. GlNR1 and GlNR2 interact in vivo
The synergistic effect of the two nitroreductases (see Fig. 3) sug-
gested a physical interaction of the two enzymes prompting us to
performpull-downassaysusingHA-taggedGlNR1andGlNR2asbaits.
These pull-down assays were used for the identiﬁcation of proteins
which speciﬁcally bind to these nitroreductases in G. lamblia. Crude
extracts from G. lamblia WBC6 expressing the corresponding con-
structs were aﬃnity-puriﬁed using anti-HA-antibodies immo-
bilised on beads followed by mass spectrometry. Under high strin-
gency conditions, HA-tagged nitroreductase GlNR1 co-puriﬁedwith
GlNR2 and with a couple of other proteins including fructose-
bisphosphate aldolase (Table 2). Conversely, HA-tagged GlNR2 co-
puriﬁed with GlNR1 and with two other proteins, namely, fructose-
bisphosphate aldolase andornithine carbamoyl-transferase (Table 3).
Immunoblot analysis usinganantibody speciﬁc forGlNR1andananti-
HAantibody showed thepresenceof GlNR1 in the immunoprecipitate
of GlNR2-3xHA. GlNR2 was not cross reactive with GlNR1. (Fig. 4).
4. Discussion
Like some other antiparasitic nitro drugs, metronidazole is con-
sidered as a prodrug that is activated by partial reduction. This
reaction is supposed to form a toxic radical (Docampo and Moreno,
1984), or partially reduced nitroso- or hydroxylamine-intermediates
(Moreno and Docampo, 1985), causing DNA damage (Sisson et al.,
2000). Conversely, complete reduction results in detoxiﬁcation of
nitro compounds thus allowing various bacteria to use toxic com-
pounds such as trinitrotoluene as carbon sources (Kutty and Bennett,
2005). Our results obtained with MTT as a ﬁnal electron acceptor
suggest that both nitroreductases are multifunctional and able to
Table 1
Activity of recombinant G. lamblia nitroreductases (GlNR1 and GlNR2) with various
nitro- and non-nitro compounds (0.1 mM) as substrates. Functional assays were per-
formed with MTT as chromogenic electron acceptor. Electron donor was NADH or
NADPH if speciﬁed. The reaction was performed at 37 °C and stopped after various
time points by addition of one volume pure ethanol. Mean values (±SE) are given
for three replicates after subtraction of enzyme and substrate blanks.
Substrate GlNR1 GlNR2
(ΔA590 min−1 mg prot−1)
Menadione 22.9 ± 0.4 16.2 ± 0.2
Menadione NADPH 1.8 ± 0.2 0.2 ± 0.1
Dicoumarol 3.1 ± 0.2 0.8 ± 0.1
Menadione + dicoumarol 27.2 ± 0.3 14.5 ± 0.1
Ubiquinone (coenzyme Q10) 2.8 ± 0.1 1.8 ± 0.2
FAD 11.8 ± 0.4 8.9 ± 0.9
Dinitrotoluene 5.2 ± 0.3 2.8 ± 0.2
Dinitrotoluene NADPH 0.9 ± 0.3 0.3 ± 0.1
7-Nitrocoumarine 10.6 ± 0.3 6.5 ± 0.5
Dinitrophenol 5.9 ± 0.4 0.2 ± 0.1
Nitrophenol 2.9 ± 0.1 2.6 ± 0.1
Metronidazole 2.8 ± 0.2 1.7 ± 0.1
Nitazoxanide 2.7 ± 0.2 1.9 ± 0.1
CB1954 3.0 ± 0.1 1.7 ± 0.1
C17 2.1 ± 0.2 0.9 ± 0.1
Fig. 3. Activity of recombinant G. lamblia nitroreductases GlNR1 (NR1) and GlNR2
(NR2) with 7-nitrocoumarine as a substrate (0.1 mM) and with NADH as an elec-
tron donor. The reaction was performed at 37 °C with GlNR1, GlNR2 alone (125 ng
each) or together (62.5 ng each) and stopped after various time points by addition
of one volume HCl 0.05 M. Formation of 7-aminocoumarin was quantiﬁed by ﬂuo-
rimetry (excitation at 365 nm, emission at 455 nm). Mean values (±SE) are given for
three replicates. Values marked by asterisks are signiﬁcantly different from each other
(paired t-test, two-sided, *p < 0.01).
Table 2
Proteins interacting with HA-tagged GlNR1 in vivo. G. lamblia WBC6was transformed
with GlNR1-3xHA. Crude extracts were aﬃnity-puriﬁed using anti-HA-antibodies
immobilised on beads followed by mass spectrometry. A control experiment was
performed with crude extract fromWBC6 expressing no recombinant protein. Only
hits with highest stringency, namely, minimal mascot score of 95 for peptide
probability, a protein probability of 95% and a minimum of 2 unique peptides per
protein, are shown.
Name Accession-N° Molecular
weight (kDa)
Unique
peptides (N°)
Axoneme-associated
protein GASP-180
GL50803_137716 175 4
Fructose-bisphosphate
aldolase
GL50803_11043 35 3
GlNR2 (Fd-NR1) GL50803_6175 31 2
Hypothetical protein GL50803_9183 214 2
TCP1-chaperon-subunit
gamma
GL50803_17411 62 2
Phosphoglycerate kinase GL50803_90872 44 2
Arginyl-tRNA-synthetase GL50803_10521 70 2
Vacuolar ATP-synthase
catalytic subunit A
GL50803_7532 72 2
Malate dehydrogenase GL50803_3331 35 2
Table 3
Proteins interacting with HA-tagged GlNR2 in vivo. G. lamblia WBC6was transformed
with GlNR2-3xHA. Crude extracts were aﬃnity-puriﬁed using anti-HA-antibodies
immobilised on beads followed by mass spectrometry. A control experiment was
performed with crude extract fromWBC6 expressing no recombinant protein. Only
hits with highest stringency, namely, minimal mascot score of 95 for peptide
probability, a protein probability of 95% and a minimum of 2 unique peptides per
protein, are shown.
Name Accession-N° Molecular
weight (kDa)
unique
peptides (N°)
GlNR1 (Fd-NR2) GL50803_22677 29 15
Fructose-bisphosphate
aldolase
GL50803_11043 35 2
Ornithine carbamoyl-
transferase
GL50803_10311 36 2
41J. Müller et al./International Journal for Parasitology: Drugs and Drug Resistance 5 (2015) 37–43
use a variety of nitro compounds as substrates.With 7-nitrocoumarin
as a substrate, full reduction to the corresponding 7-aminocoumarin
can be investigated (Wagner, 2009). In our hands, GlNR2 is twice
as effective as GlNR1 in this reaction indicating that it performs the
full reduction rather than a partial reduction. When mixed, both
enzymes act synergistically.
In E. coli, expression of GlNR1 increases the susceptibility to
nitazoxanide exclusively under semi-aerobic growth conditions
whereas susceptibility to metronidazole is increased under semi-
aerobic and aerobic conditions. In contrast, GlNR2 decreases the
susceptibility to metronidazole under both growth conditions con-
ﬁrming previous results (Nillius et al., 2011; Müller et al., 2013).
Interestingly, expression of both enzymes has the same effects as
expression of GlNR2 alone suggesting that E. coli BL21(DE3) is able
to express endogenous nitroreductases even under aerobic growth
conditions what is fully in frame with previously published results
(Zenno et al., 1996a, 1996c; Valle et al., 2012). While these endog-
enous nitroreductases reduce metronidazole to toxic intermediates,
GlNR2 acts antagonistically and eliminates metronidazole toxicity
in E. coli. Susceptibility of E. coli to metronidazole has been re-
ported earlier (Olekhnovich et al., 2009; Nillius et al., 2011). The
results with nitroreductase-expressing E. coli and the results ob-
tained with 7-nitrocoumarin in functional assays suggest that GlNR1
preferentially performs a partial reduction of nitro compounds yield-
ing toxic intermediates. Conversely, GlNR2 is able to entirely reduce
a nitro compound thus generating a non-toxic end product, e.g. the
corresponding amine.
Our experiments show, however, that nitro compounds are not
the best substrates for both enzymes having highest activities on
menadione as substrate. This quinone reductase activity is not in-
hibited by dicoumarol as it is the case for typical mammalian
nitroreductases such as the humanquinone reductaseNQO1 (Müller
andHemphill, 2011).Moreover, bothenzymes reduce freeFAD. Similar
multifunctional nitroreductases have been identiﬁed in various bac-
teria including E. coli (Zenno et al., 1996a, 1996b, 1996c), Lactobacillus
plantarum (Guillén et al., 2009), Salmonella typhimurium (Yanto et al.,
2010) and in eukaryotes such as Trypanosoma cruzi (Hall et al., 2012),
The genome of G. lambliaWBC6 contains three putative NADPH de-
pendent quinone reductases, namely, Gl50803_15004 (18.6 kDa),
Gl50803_17150 (18.5 kDa), andGl50803_17151 (19.5 kDa). Only one,
Gl50803_15004, has been previously characterised in detail. This
enzyme reducesmenadioneusingNADPHaspreferredelectrondonor
(Sanchez et al., 2001).
The biological function of GlNR1 and GlNR2 could be the re-
duction of quinones and other heterocyclic compounds in essential
steps of intermediate metabolism. Menadione is not a quinone
present in Giardia and is even toxic (Paget et al., 2004). This toxic-
ity may be due to a partial reduction of menadione to the
corresponding semiquinone. Other potential substrates such as FAD
and ubiquinone (Ellis et al., 1994) are, however, present in Giardia
and play an important role in intermediate metabolism.
This could explain why knock-down approaches have failed, so
far in our hands, and why a nitroreductase is essential for Leish-
mania donovani (Voak et al., 2013). From an evolutionary point of
view, the reduction of nitro compounds could be a side effect without
negative selective pressure until a nitro compound yielding toxic
intermediates after reduction comes into play. Then, the presence
of an otherwise beneﬁcial activity turns into a disaster for the cell.
In the presence of sublethal concentrations of the nitro com-
pound, resistance formation is then achieved not by a mere down-
regulation of the nitroreductase responsible for the toxic intermediate
formation, but rather by a complete re-organisation of cellular me-
tabolism as exempliﬁed by the resistance formation of WBC6 against
nitazoxanide (Müller et al., 2008).
Pull-down assays with both nitroreductases as baits and
immunoblot analysis show that both enzymes interact with each
other. Moreover, they may also interact with fructose-bisphosphate
aldolase, a key enzyme of glycolysis. The signiﬁcance of this ﬁnding
is unclear and will be studied in further immunoprecipitation ex-
periments using fructose-bis-phosphate aldolase as a bait.
Novel promising techniques like conditional knock-outs
(Wampﬂer et al., 2014) could open the way to understand the bi-
ological function of nitroreductases in G. lamblia.
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